Weekly Research Analysts’ Ratings Changes for REGENXBIO (RGNX)

Several analysts have recently updated their ratings and price targets for REGENXBIO (NASDAQ: RGNX):

  • 11/9/2026 – REGENXBIO was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
  • 11/7/2026 – REGENXBIO was downgraded by Wall Street Zen from “hold” to “sell”.
  • 11/6/2026 – REGENXBIO was given a new $18.00 price target by Mizuho.
  • 11/6/2026 – REGENXBIO had its “positive” rating reaffirmed by UBS Group.
  • 10/5/2026 – REGENXBIO is now covered by Mizuho. They set an “outperform” rating and a $22.00 price target on the stock.
  • 10/5/2026 – REGENXBIO was upgraded by Mizuho to “strong-buy”.
  • 9/28/2026 – REGENXBIO had its “buy” rating reaffirmed by HC Wainwright.

REGENXBIO Trading Up 0.3%

Shares of NASDAQ RGNX opened at $7.26 on Thursday. The firm has a market cap of $480.03 million, a P/E ratio of -2.26 and a beta of 1.24. The business’s 50 day moving average is $7.56 and its 200-day moving average is $8.84. REGENXBIO Inc. has a 1-year low of $5.45 and a 1-year high of $16.19.

REGENXBIO (NASDAQ:RGNX – Get Free Report) last announced its earnings results on Thursday, November 5th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.67. REGENXBIO had a negative net margin of 113.85% and a negative return on equity of 203.98%. The company had revenue of $9.16 million during the quarter, compared to analysts’ expectations of $10.89 million. Analysts forecast that REGENXBIO Inc. will post -3.01 EPS for the current year.

REGENXBIO Inc. is a biotechnology company focused on developing gene therapies for inherited diseases and other serious conditions. Founded in 2008 and headquartered in Rockville, Maryland, the company uses its proprietary NAV AAV gene-delivery platform to develop treatments intended to deliver genetic material to patients’ cells. Its research programs have included RGX-314, an investigational gene therapy for retinal diseases such as wet age-related macular degeneration, and candidates for conditions including Hunter syndrome and Duchenne muscular dystrophy.

Read More

Receive News & Ratings for REGENXBIO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc and related companies with MarketBeat.com's FREE daily email newsletter.